Alto Neuroscience rallies over $40m

Alto Neuroscience, a provider of a clinical-stage pipeline of precision psychiatry medicines, has raised over $40 million in funding.

14 October 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles